A PHASE II, RANDOMIZED, OPEN-LABEL STUDY EVALUATING TWO INAVOLISIB DOSE LEVELS IN COMBINATION WITH FULVESTRANT IN PARTICIPANTS WITH PIK3CA-MUTATED, HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO46063 (optINAVO))

Principal Investigator

Dr Mark Henry Tuthill

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1013121